TW202204400A - 適用於使纖維蛋白凝塊溶解之融合蛋白質及含有該融合蛋白質之醫藥組合物 - Google Patents

適用於使纖維蛋白凝塊溶解之融合蛋白質及含有該融合蛋白質之醫藥組合物 Download PDF

Info

Publication number
TW202204400A
TW202204400A TW110111960A TW110111960A TW202204400A TW 202204400 A TW202204400 A TW 202204400A TW 110111960 A TW110111960 A TW 110111960A TW 110111960 A TW110111960 A TW 110111960A TW 202204400 A TW202204400 A TW 202204400A
Authority
TW
Taiwan
Prior art keywords
fusion protein
amino acid
acid sequence
antibody
seq
Prior art date
Application number
TW110111960A
Other languages
English (en)
Chinese (zh)
Inventor
松村保広
花岡慎悟
西條信史
Original Assignee
國立研究開發法人國立癌症研究中心
日商凜研究所股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立研究開發法人國立癌症研究中心, 日商凜研究所股份有限公司 filed Critical 國立研究開發法人國立癌症研究中心
Publication of TW202204400A publication Critical patent/TW202204400A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
TW110111960A 2020-03-31 2021-03-31 適用於使纖維蛋白凝塊溶解之融合蛋白質及含有該融合蛋白質之醫藥組合物 TW202204400A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-062316 2020-03-31
JP2020062316 2020-03-31

Publications (1)

Publication Number Publication Date
TW202204400A true TW202204400A (zh) 2022-02-01

Family

ID=77928922

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110111960A TW202204400A (zh) 2020-03-31 2021-03-31 適用於使纖維蛋白凝塊溶解之融合蛋白質及含有該融合蛋白質之醫藥組合物

Country Status (8)

Country Link
US (1) US12509507B2 (https=)
EP (1) EP4129334A4 (https=)
JP (1) JP7704339B2 (https=)
CN (1) CN115552012A (https=)
AU (1) AU2021246398A1 (https=)
CA (1) CA3178856A1 (https=)
TW (1) TW202204400A (https=)
WO (1) WO2021200922A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4506458A1 (en) 2022-04-08 2025-02-12 RIN Institute Inc. Antibody binding to fibrin, fibrinolytic protein containing antibody, and pharmaceutical formulation containing protein
CN117110404A (zh) * 2023-08-24 2023-11-24 山东大学 一种基于纤维蛋白-核酸适配体复合结构的石墨烯场效应晶体管微纳生物传感器及其应用
WO2025178058A1 (ja) * 2024-02-19 2025-08-28 株式会社凜研究所 フィブリンに結合する抗体および当該抗体を含むフィブリン溶解性タンパク質および当該タンパク質を含む医薬製剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5390286A (en) 1985-01-25 1986-08-13 Sagami Chemical Research Center Stabilized human prourokinase
JPS62143686A (ja) * 1985-01-25 1987-06-26 Sagami Chem Res Center 安定化されたヒト−プロウロキナ−ゼ
ES2043610T3 (es) * 1986-01-31 1994-01-01 Sagami Chem Res Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno.
US5204255A (en) * 1986-01-31 1993-04-20 Sagami Chemical Research Center Hybrid tissue plasminogen activator/urokinase polypeptides
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use
US5571708A (en) * 1993-04-19 1996-11-05 Bristol-Myers Squibb Company Thrombin-activatable plasminogen activator
JP2006241109A (ja) 2005-03-04 2006-09-14 Paion Deutschland Gmbh ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質
ES2673583T3 (es) 2013-02-28 2018-06-22 National Cancer Center Anticuerpo contra fibrina insoluble
SG11201910113PA (en) 2017-05-02 2019-11-28 Nat Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate

Also Published As

Publication number Publication date
JP7704339B2 (ja) 2025-07-08
US12509507B2 (en) 2025-12-30
AU2021246398A1 (en) 2022-11-03
US20240218058A1 (en) 2024-07-04
EP4129334A4 (en) 2024-06-12
CN115552012A (zh) 2022-12-30
EP4129334A1 (en) 2023-02-08
WO2021200922A1 (ja) 2021-10-07
JPWO2021200922A1 (https=) 2021-10-07
CA3178856A1 (en) 2021-10-07
AU2021246398A8 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US20210309727A1 (en) Activatable antibodies having non-binding steric moieties and methods of using the same
US20240398914A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
JP2024170616A (ja) Ｍａｓｐ－２依存性の補体活性化を阻害するための組成物
JP7704339B2 (ja) フィブリンクロットを溶解させることに適した融合タンパク質および当該融合タンパク質を含む医薬組成物
KR20160074510A (ko) 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
ZA200505114B (en) Chimeric and humanized antibodies to a5p"1 integrin that modulate angiogenesis
JP2010522559A (ja) アミロイドベータペプチドを分解できる融合タンパク質
US20210246212A1 (en) Anti-gpiib/iiia antibodies and uses thereof
CN113056304A (zh) 用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途
KR20180132831A (ko) 죽상동맥경화증의 치료 방법
JP2001502895A (ja) アルファ―２―抗プラスミンに対するキメラ、ヒト化および一本鎖抗体
CN113631579B (zh) 组织纤溶酶原激活物抗体及其使用方法
CN115297927A (zh) 血浆激肽释放酶抑制剂及其用于治疗儿科遗传性血管性水肿发作的用途
JP6971946B2 (ja) 反応抑制的抗体による特異的プラスミン不活性化
WO2004041296A2 (en) Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
CA3158862A1 (en) Polypeptide inhibitors of neutrophil elastase activity and uses thereof
CN102558354B (zh) 一株抗人血小板膜糖蛋白Ibα人鼠嵌合型单克隆抗体及其应用
EP1200562B1 (en) Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders
Hanaoka et al. A novel and potent thrombolytic fusion protein consisting of anti-insoluble fibrin antibody and mutated urokinase
EP4506458A1 (en) Antibody binding to fibrin, fibrinolytic protein containing antibody, and pharmaceutical formulation containing protein
US20040198660A1 (en) Tissue factor antagonist and protein C polypeptide compositions
CN118922548A (zh) 与纤维蛋白结合的抗体、含有该抗体的纤维蛋白溶解性蛋白质和含有该蛋白质的药物制剂
WO2025178058A1 (ja) フィブリンに結合する抗体および当該抗体を含むフィブリン溶解性タンパク質および当該タンパク質を含む医薬製剤
JP2019214577A (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
HK1220132B (en) Combination therapy using a factor xii inhibitor and a c1-inhibitor